Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...
Chart does not reflect overnight price.
or Create free account By creating an account using any of the options above, you agree to the & XFOR X4 Pharmaceuticals, Inc. Earnings Date & History ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback